1. Agren H, Oreland L. Early morning awakening in unipolar with higher levels of platelet MAO activity. Psychiatry Res 1982;7:245–254.

2. Agren H. Depressive symptom patterns and urinary MHPG excretion. Psychiatry Res 1982;6:185–196.

3. Amsterdam JD, Maislin G, Skolnick B, et al. Multiple hormonal responses to clonidine in depressed patients and volunteers. Biol Psychiatry 1989;26:265–278.

4. Annseau M, Von Frenckell R, Cerfontaine JL, et al. Neuroendocrine evaluation of catecholaminergic transmission in mania. Psychiatry Res 1987;22:193–206.

5. Bowden CL, Koslow S, Maas JW, et al. Changes in urinary catecholamines and their metabolites in depressed patients treated with amitriptyline or imipramine. J Psychiatr Res 1987;21:111–128.

6. Coupland N, Glue P, Natt DJ. Challenge tests: assessment of the noreadrenergic and GABA systems in depression and anxiety disorders. Mol Aspects Med 1992;13:221–247.

7. De leon-Jones FD, Maas JW, Dekirmenjian H, et al. Diagnostic subgroups of affective disorders and their urinary excretion of catecholamine metabolites. Am J Psychiatry 1975;132:1141–1148.

8. Delgado PL Miller HL, Salomon RM, et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 1993;29:389–396.

9. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of anti-depressant action: reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990;47:411–418.

10. DeParmentier F, Cheetham SC, Crompton MR, et al. Brain b-adrenoreceptor binding sites in antidepressant-free depressed suicide victims. Brain Res 1990;525:71–77.

11. Esler M, Turbott JT, Schwartz R, et al. The peripheral kinetics of norepinephrine in depressive illness. Arch Gen Psychiatry 1982;39:295–300.

12. Extein I, Tallman J, Smith CC, et al. Changes in lymphocyte beta-adrenergic receptors in depression and mania. Psychiatry Res 1979;1:191–197.

13. Garcia-Sevilla JA, Guimon J, Garcia-Vallejo P, et al. Biochemical and functional evidence of supersensitive platelet a2-adrenoreceptors in major affective disorder: effect of long-term lithium carbonate treatment. Arch Gen Psychiatry 1986;43:51–57.

14. Garcia-Sevilla JA, Pardo D, Giralt MT, et al. a2-Adrenoreceptor-mediated inhibition of platelet adenylate cyclase and induction of aggregation in major depression: effect of long-term antidepressant drug treatment. Arch Gen Psychiatry 1990;47:125–132.

15. Garvey MJ, Hollon S, Evans M, DeRubeis RJ, Tuason VB, et al. The association of MHPG to dexamethasone suppression test status. Psychiatry Res 1988;24:223–230.

16. Georgotas A, Schwertzer J, McCue RE, et al. Clinical and treatment effects on 3-H-clonodine and 3-H-imipramine binding in elderly depressed patients. Life Sci 1987;40:2137–2143.

17. Goodwin FK, Post RM. Studies of amine metabolites in affective illness and in schizophrenia: a comparative analysis. In: Freedman DX, ed. Biology of the major psychoses. New York: Raven Press; 1975:299–232.

18. Healy D, Halloran AO, Carney PA, et al. Peripheral adrenoreceptors and serotonin receptors in depression; changes associated with response to treatment with trazodone or amitriptyline. J Affect Dis 1985;9:285–296.

19. Hollister LE, David KL, Berger PA. Subtypes of depression based on excretion of MHPG and response to nortriptyline. Arch Gen Psychiatry 1980;37:1107–1110.

20. Jimerson DC, Insel TR, Reus VI, Kopin IJ. Increased plasma MHPG in dexamethasone-resistant depressed patients. Arch Gen Psychiatry 1983;40:173–176.

21. Johnson MR, Lydiard RB, Morton WA, et al. Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients. J Psychiatr Res 1993;27:161–172.

22. Karege F, Bovier PH, Gaillard JM, Tissot R. Plasma MHPG and AMDP depression relations, evolution and drug effect in a follow-up study of depressed patients. Hum Psychopharmacol 1991;6:11–17.

23. Koslow SH, Maas JW, Bowden CL, et al. CSF and urinary biogenic amines and metabolites in depression and mania. Arch Gen Psychiatry 1983;40:999–1010.

24. Loo H, Poirier MF, Dennis T, et al. Lack of correlation between DST results and urinary MHPG in depressed inpatients. J Neural Transm 1988;72:121–130.

25. Maas JW, Fawcett JA, Dekirmenjian H. Catecholamine metabolism, depressive illness, and drug response. Arch Gen Psychiatry 1972;26:252–262.

26. Maas JW, Koslow SH, David J, et al. Catecholamine metabolism and disposition in healthy and depressed subjects. Arch Gen Psychiatry 1987;44:337–344.

27. Maas JW, Koslow SH, Katz MM, et al. Pretreatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs. Am J Psychiatry 1984;141:10:1159–1171.

28. Maes M, Minner B, Suy E, et al. Coexisting dysregulations of both the sympathoadrenal system and hypothalamic-pituitary-adrenal-axis in melancholia. J Neural Transm [Gen Sect] 1991;85:195–210.

29. Maj M, Ariano MG, Arena F, Kemali D. Plasma cortisol, catecholamine and cyclic AMP levels, response to dexamethasone suppression test and platelet MAO activity in manic-depressive patients. Neuropsychobiology 1984;11:168–173.

30. Mann JJ, Mahler JC, Wilner RJ, et al. Normalization of blunted lymphocyte N-adrenergic responsivity in melancholic inpatients by a course of electroconvulsive therapy. Arch Gen Psychiatry 1990;47:461–464.

31. Mann JJ, Stanley M, McBride PA, et al. Increased serotonin2 and b -adrenergic receptor binding in the frontal corties of suicide victims. Arch Gen Psychiatry 1986;43:954–969.

32. Meltzer HY, Lowry MT, Locascio JL. Platelet MAO activity and the cortisol response to dexamethasone in depression. Biol Psychiatry 1988;24:129–142.

33. Michel MC, Regan JW, Gerhardt MA, et al. Noradrenergic [3H]idazoxan binding sites are physically distinct from alpha-2 adrenergic receptors. Mol Pharmacol 1990;37:65–68.

34. Miller HL, Delgado PL, Salomon RM, et al. Alpha-methyl-para-tyrosine in drug-free depressed patients. Presented at the 146th annual meeting of the American Psychiatric Association. New Res Abst 1993;476.

35. Mitchell PB, Bearn JA, Corn TH, Checkley SA. Growth hormone response to clonidine after recovery in patients with endogenous depression. Br J Psychiatry 1988;152:34–38.

36. Mooney JJ, Schatzberg AF, Cole JO, et al. Rapid antidepressant response to alprazolam in depressed patients with high catecholamine output and heterologous desensitization of platelet adenylate cyclase. Biol Psychiatry 1988;23:543–559.

37. Mooney JJ, Schatzberg AF, Cole JO, et al. Urinary 3-methoxy-4-hydroxyphenylglycol and the depression-type score as predictors of differential responses to antidepressants. J Clin Psychopharmacol 1991;11:339–343.

38. Muscettola G, Potter WZ, Pickard D, et al. Urinary 3-methoxy-4-hydroxyphenylglycol and major affective disorders. Arch Gen Psychiatry 1984;41:337–342.

39. Pandey GN, Sharma RP, Janicak PH, Davis JM. Monoamine oxidase and cortisol response in depression and schizophrenia. Psychiatry Res 1992;44:1–8.

40. Pandey GN, Janicak PG, Javaid JI, et al. Increased 3-H-clonidine bindings in the platelets of patients with depressive and schizophrenic disorders. Psychiatry Res 1989;28:73–88.

41. Petty F, Kramer GL, Hedricksen W. GABA and depression. In: Mann JJ, Kupfer DJ, eds. Biology of depressive disorders, part A: a systems perspective. New York: Plenum Press; 1993:79–108.

42. Potter WZ, Grossman F, Rudoerfer MV. Noradrenergic function in depressive disorders. In: Mann JJ, Kupfer DJ, eds. Biology of depressive disorders, part A: a systems perspective. New York: Plenum Press; 1993:1–27.

43. Potter WZ, Karoum F, Linnoila M. Common mechanism of action of biochemically "specific" antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 1984;8:153–161.

44. Potter WZ, Linnoila M. Biochemical classifications of diagnostic subgroups and D-type scores. Arch Gen Psychiatry 1989;46:269–271.

45. Rosenbaum AH, Maruta T, Schatzberg AF, et al. Toward a biochemical classification of depressive disorders. VII: urinary free cortisol and urinary MHPG in depressions. Am J Psychiatry 1983;140:314–318.

46. Rothschild AJ, Schatzberg AF, Langlais PJ, Lerbinger JE, Miller MM, Cole JO. Psychotic and nonpsychotic depressions. I: Comparison of plasma catecholamines and cortisol measures. Psychiatry Res 1987;20:143–153.

47. Roy A, Jimerson DC, Pickar D. Plasma MHPG in depressive disorders and relationship to the dexamethasone suppression test. Am J Psychiatry 1986;143:7:846–851.

48. Roy A, Pickar D, De Jong J, et al. Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine. Arch Gen Psychiatry 1988;45:849–857.

49. Roy A, Pickar D, Linnoila M, et al. Plasma norepinephrine level in affective disorders. Arch Gen Psychiatry 1985;42:1181–1185.

50. Rubin AL, Price LH, Charney DS, Heninger GR. Noradrenergic function and the cortisol response to dexamethasone in depression. Psychiatry Res 1985;15:5–15.

51. Rudorfer MV, Ross RS, Linnoila M, et al. Exaggerated arthostatic responsivity of plasma norepinephrine in depression. Arch Gen Psychiatry 1985;42:1186–1192.

52. Samson JA, Mirin SM, Griffin M, et al. Urinary MHPG and clinical symptoms in unipolar depressed patients. Psychiatry Res [in press].

53. Samson JA, Mirin SM, Hauser SJ, et al. Learned helplessness and urinary MHPG levels in unipolar depression. Am J Psychiatry 1992;149:806–809.

54. Schatzberg AF, Orsulak PJ, Rosenbaum AH, et al. Toward a biochemical classification of depressive disorders. V: heterogeneity of unipolar depressions. Am J Psychiatry 1982;139:471–475.

55. Schatzberg AF, Rosenbaum AH, Orsulak PJ, et al. Toward a biochemical classification of depressive disorders. III: pretreatment of urinary MHPG levels as predictors of response to treatment with maprotiline. Psychopharmacology 1981;75:34–38.

56. Schatzberg AF, Rothschild AJ, Gerson B, et al. Toward a biochemical classification of depressive disorders. IX: DST results and platelet MAO activity. Br J Psychiatry 1985;146:633–637.

57. Schatzberg AF, Samson JA, Bloomingdale KL, et al. Toward a biochemical classification of depressive disorders. X: urinary catecholamines, their metabolites, and D-type scores in subgroups of depressive disorders. Arch Gen Psychiatry 1989;46:260–268.

58. Schatzberg AF, Samson JA, Schildkraut JJ, et al. Relationships between catecholamine and cortisol measures in depressed patients. Presented at the American College of Neuropsychopharmacology Annual Meeting. Maui, Hawaii, 1989.

59. Schatzberg AF, Bowden CL, Rosenbaum AH, Schildkraut JJ. Prediction of response to fluoxetine versus desipramine. CME Syllabus and Proceedings Summary, 145th Annual Meeting. Washington, DC: American Psychiatric Association; 1992:44 (No. 25D).

60. Schildkraut JJ, Keeler BA, Grab EL, et al. MHPG excretion and clinical classification in depressive disorders. Lancet 1973;1:1251–1252.

61. Schildkraut JJ, Keeler BA, Rogers MP, et al. Catecholamine metabolism in affective disorders: a longitudinal study of a patient treated with amitriptyline and ECT. Psychosom Med 1973;34:470 and 35:274 (abst).

62. Schildkraut JJ, Orsulak PJ, LaBrie RA, et al. Toward a biochemical classification of depressive disorders. II: application of multiariate discriminant function analysis of data on urinary catecholamines and metabolites. Arch Gen Psychiatry 1978;35:1436–1439.

63. Schildkraut JJ, Orsulak PJ, Schatzberg AF, et al. Toward a biochemical classification of depressive disorders. I: differences in urinary excretion of MHPG and other catecholamine metabolites in clinically defined subtypes of depressions. Arch Gen Psychiatry 1978;35:1427–1433.

64. Schildkraut JJ. Norepinephrine metabolites as biochemical criteria for classifying depressive disorders and predicting response to treatment. Preliminary findings. Am J Psychiatry 1973;130:695–699.

65. Schildkraut JJ. Catecholamine metabolism and affective disorders: studies of MHPG excretion. In: Usdin E, Snyder S, eds. Frontiers in catecholamine research. New York: Pergamon Press; 1973:1165–1171.

66. Schildkraut, JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509–522.

67. Sharma RP, Janicak PG, Javaid JI, et al. Platelet MAO inhibition, urinary MHPG, and leukocyte beta-adrenergic receptors in depressed patients treated with phenelzine. Am J Psychiatry 1990;147:1318–1321.

68. Shopsin B, Gershon S, Goldstein M, et al. Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacol Commun 1975; 2:239–249.

69. Siever LJ, Kafka MS, Targum SM, et al. Platelet alpha adrenergic binding and biochemical responsiveness in depressed patients and controls. Psychiatry Res 1984;11:287–302.

70. Siever LJ, Uhde TW, Jimerson DC, et al. Differential inhibitory noradrenergic responses to clonidine in 25 depressed patients and 25 normal control subjects. Am J Psychiatry 1984;141:733–741.

71. Stokes PE, Frazer A, Casper R. Unexpected neuroendocrine-transmitter relationships. Psychopharmacol Bull 1981;17:72–75.

72. Stokes PE, Maas JW, Davis JM, et al. Biogenic amine and metabolite levels in depressed patients with high versus normal hypothalamic–pituitary–adrenocortical activity. Am J Psychiatry 1987;144:7:868–872.

73. Sulser F, Vetulani J, Mobley PL. Mode of action of antidepressant drugs. Biochem Pharmacol 1978;27:257–271.

74. Swann AC, Koslow SH, Katz MM, et al. Lithium carbonate treatment of mania. Arch Gen Psychiatry 1987;44:345–354.

75. Swann AC, Secunda SK, Stokes PE, et al. Stress, depression, and mania; relationship between perceived role of stressful events and clinical and biochemical characteristics. Acta Psychiatr Scand 1990;81:389–397.

76. Westiuk ES, Steiner M, Burns T. Studies on leukocyte b -adrenergic receptors in depression: A critical appraisal. Life Sci 1990;47:85–105.

77. Zhou D, Shen Y, Shu L, Lo H. Dexamethasone suppression test and urinary MHPG—SO4 determination in depressive disorders. Biol Psychiatry 1987;22:883–891.